Annexon (ANNX) Current Deferred Revenue (2019 - 2021)

Annexon's (ANNX) quarterly Current Deferred Revenue came in at $398000.0 in Q1 2021, up 1.79% quarter-over-quarter from $391000.0 in Q4 2020.

Annexon (ANNX) Current Deferred Revenue (2019 - 2021) Analysis & Trends

Annexon's Current Deferred Revenue history runs 3 years deep, the most recent figure standing at $398000.0 for Q1 2021.

  • On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $398000.0 in Q1 2021; TTM through Mar 2021 was $398000.0, a N/A change from a year earlier, with the FY2020 full-year figure at $391000.0, up 6.83% from the prior year.
  • Current Deferred Revenue advanced to $398000.0 in Q1 2021 per ANNX's latest filing, from $391000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $398000.0 in Q1 2021 and bottomed at $366000.0 in Q4 2019.
  • The 3-year median for Current Deferred Revenue is $385000.0 (2020), against an average of $383600.0.
  • Biggest YoY gain for Current Deferred Revenue was 6.83% in 2020; the steepest drop was 6.83% in 2020.
  • Year by year, Current Deferred Revenue stood at $366000.0 in 2019, then gained by 6.83% to $391000.0 in 2020, then advanced by 1.79% to $398000.0 in 2021.
  • Per Business Quant, the three latest ANNX Current Deferred Revenue figures stand at $398000.0 (Q1 2021), $391000.0 (Q4 2020), and $385000.0 (Q3 2020).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Annexon 1.03 Bn 804.24 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2021 398,000.00
Dec 31, 2020 391,000.00
Sep 30, 2020 385,000.00
Jun 30, 2020 378,000.00
Dec 31, 2019 366,000.00